Endogenous tumour necrosis factor-alpha sensitise melanoma cells to glucosaminylmuramyl dipeptide.
Flow cytometry was used to demonstrate that cultured human melanoma BRO cells expressed membrane-bound tumour necrosis factor-alpha (TNF-alpha) and were able to release TNF-alpha upon treatment with glucosaminylmuramyl dipeptide (GMDP). The released TNF-alpha was shown to prime melanoma cells, previously unable to respond to GMDP by increasing expression of melanoma-associated antigens, making them sensitive to GMDP treatment.
Valyakina
T I
TI
Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow.
Komaleva
R L
RL
Petrova
E E
EE
Malakhov
A A
AA
Shamborant
O G
OG
Andronova
T M
TM
Nesmeyanov
V A
VA
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D000951:Antigens, Neoplasm / Q000096:biosynthesis / Q000187:drug effects; D002474:Cell-Free System / Q000502:physiology; D017077:Culture Media, Conditioned / Q000494:pharmacology; D005434:Flow Cytometry; D006801:Humans; D008545:Melanoma / Q000276:immunology / Q000378:metabolism*; D051379:Mice; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000502:physiology*
D000276:Adjuvants, Immunologic; D000951:Antigens, Neoplasm; D017077:Culture Media, Conditioned; D014409:Tumor Necrosis Factor-alpha; D000119:Acetylmuramyl-Alanyl-Isoglutamine; C023868:N-acetyl-beta-glucosaminyl-N-acetylmuramyl-alanylisoglutamine